drugset
drugset / Trial / NCT05901311

A Study of [14C]-LY3537982 in Healthy Participants

NCT05901311 ↗

Phase 1 Completed 16 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to conduct blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 in healthy participants. This study will involve a single dose of 14C radiolabeled LY3537982. This means that a radioactive tracer substance, C14, will be incorporated into the study drug LY3537982 to investigate the study drug and its breakdown products and to find out how much of these passes from blood into urine, feces and expired air. The study will also evaluate the safety and tolerability of LY3537982. The study will be conducted in two parts. The study will last up to 71 days and 61 days for part 1 and 2, respectively.

Timeline

Start
2023-06-05
Primary completion
2023-08-10
Completion
2023-08-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Olomorasib Small molecule — Oral

Indications

No indication recorded.